The incidence and mortality of prostate cancer from 1957 to 1991 were studied in the Cancer Registry of Norway. The age-adjusted incidence rate increased from 26.3 to 46.6 per 100,000 person-years during the period, and more than 2000 cases are now registered yearly. The increase tends to be higher in the younger age groups, 50-59 years, and among the oldest, 90+ years. An increase was also found in cause-specific mortality, signifying a real increase in incidence over time. There is a slight urban dominance in incidence of prostate cancer. Autopsy findings account for less than 1.7% of the total. The histo- and cytological verification rate reached 94% in 1987-1991 and the percentage of localised cases was 68.4%. The median age at diagnosis in 1987-1991 was 75.1 years. Data on stage at time of diagnosis, histological differentiation and survival, reflect a small influence of earlier diagnosis. Model analysis revealed no particular birth cohort effect, either on incidence or on mortality.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0959-8049(95)00505-6DOI Listing

Publication Analysis

Top Keywords

incidence mortality
8
prostate cancer
8
incidence
5
cancer
4
cancer prostate
4
prostate norway
4
norway 1957-1991--a
4
1957-1991--a descriptive
4
descriptive study
4
study incidence
4

Similar Publications

Severe Maternal Morbidity Associated With Chronic Hypertension, Preeclampsia, and Gestational Hypertension.

JAMA Netw Open

January 2025

Magee-Womens Research Institute, Department of Obstetrics, Gynecology and Reproductive Sciences, Epidemiology and Clinical and Translational Research, University of Pittsburgh, Pittsburgh, Pennsylvania.

Importance: Chronic hypertension and preeclampsia are leading risk enhancers for maternal-neonatal morbidity and mortality. Severe maternal morbidity (SMM) indicators include heart, kidney, and liver disease, but studies have not excluded patients with preexisting diseases that define SMM. Thus, SMM risks for uncomplicated chronic hypertension specific to preeclampsia remain unclear.

View Article and Find Full Text PDF

Kidney function estimation equations: a narrative review.

Ir J Med Sci

January 2025

Department of Nephrology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Manipal, Karnataka, India.

Glomerular filtration rate (GFR) as a marker of kidney function is important in health and disease management because decreased kidney function is associated with all-cause and cardiovascular mortality, progression of kidney disease, predisposition to acute kidney injury (AKI), and for drug dosage modification. While measured glomerular filtration rate (mGFR) is acknowledged as the most accurate method for evaluating kidney function, it is at present not feasible to be applied in the clinical arena. Estimated glomerular filtration rate (eGFR) is preferred due to its convenience, cost-effectiveness, and seamless integration into standard clinical practice for kidney function evaluation.

View Article and Find Full Text PDF

An insight on the additive impact of type 2 diabetes mellitus and nonalcoholic fatty liver disease on cardiovascular consequences.

Mol Biol Rep

January 2025

Department of Pharmaceutical Sciences & Technology, BIT Mesra, Ranchi, 835215, India.

Background: Nonalcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM) are associated with a multifactorial complicated aetiology that is often coexisting and has a strong and distinct connection with cardiovascular diseases (CVDs). In order to accomplish effective and appropriate therapeutic strategies, a deeper understanding of the bidirectional interaction between NAFLD patients, NAFLD patients with T2DM, and NAFLD patients with CVDs is required to control the concomitant rise in prevalence of these conditions worldwide. This article also aims to shed light on the epidemiology and mechanisms behind the relationship between T2DM, NAFLD and the related cardiovascular consequences.

View Article and Find Full Text PDF

Background: There are limited data on duration of aromatase inhibitor (AI) and cardiovascular disease (CVD) risk in breast cancer (BC) survivors. We examined risk of CVD and mortality associated with duration of AI use in postmenopausal women with early-stage hormone receptor-positive BC.

Methods: Postmenopausal women diagnosed with hormone receptor-positive BC (n = 5,853) who used an AI were included.

View Article and Find Full Text PDF

Objectives: Serum galectin-3 (sGal-3) is a protein present in renal tubules and increases in experimental rodent models of acute kidney injury. The aim of this study was to compare sGal-3 concentrations in healthy cats and cats with ureteral obstruction (UO).

Methods: This was a retrospective study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!